Abstract

OBJECTIVE

To determine whether the different antimüllerian hormone (AMH) immunoassays on the market offer the same performance for the diagnosis of polycystic ovary syndrome (PCOS).

DESIGN

A total of 95 serum AMH samples were retrospectively evaluated for a period of 3 months in the same laboratory.

SETTING

Academic center laboratory.

PATIENT(S)

Forty-eight control women with regular menses and no hyperandrogenism and 47 patients with classic PCOS (i.e., hyperandrogenism plus oligoanovulation) attending our department for infertility.

INTERVENTION(S)

None.

MAIN OUTCOME MEASURE(S)

AMH measurement using five commercial assays. Method comparison and evaluation of the diagnostic performance by receiver operating characteristic analysis.

RESULT(S)

Values obtained with Gen II and AL-105i ELISAs were similar to those provided by EAI AMH/MIS, whereas automatic assays generated lower values. A significant mean difference was observed between Access Dxi (1.35 ng/mL) or Cobas (1.73 ng/mL) and EIA AMH/MIS ELISA. By ROC analysis each assay displayed similar efficiency for PCOS diagnosis. Sensitivities varied from 49% to 74% when setting the specificity at 92%. Cluster analysis run in the control group identified a subgroup of asymptomatic women with polycystic ovary morphology (PCOM). After exclusion of PCOM, the 95th percentile of controls was 4.2 ng/mL (30 pmol/L) with the automatic assays and 5.6 ng/mL (40 pmol/L) with the manual assays.

CONCLUSION(S)

Performance of the different AMH assays for PCOS diagnosis is comparable, providing that different threshold values are used for manual and automatic assays. Measurement of serum AMH level appears as a robust tool for the definition of PCOM.

MeSH

Fertility, Laboratories, Serum, Ovary, Infertility, Hormones, Anti-Mullerian Hormone, Diagnosis, Polycystic Ovary Syndrome, Hyperandrogenism

Cited by

• Association Between Biomarkers of Ovarian Reserve and Infertility Among Older Women of Reproductive Age. JAMA, 2017
• Could Cytochrome P450 2D6, 3A4 and 3A5 Polymorphisms Explain the Variability in Clinical Response to Clomiphene Citrate of Anovulatory PCOS Women? Front Endocrinol (Lausanne), 2022
• Potential pitfalls of reproductive direct-to-consumer testing. F S Rep, 2022
• Impact of endometriosis on oocyte morphology in IVF-ICSI: retrospective study of a cohort of more than 6000 mature oocytes. Reprod Biol Endocrinol, 2022
• Establishing an Anti-Müllerian Hormone Cutoff for Diagnosis of Polycystic Ovarian Syndrome in Women of Reproductive Age-Bearing Indian Ethnicity Using the Automated Anti-Müllerian Hormone Assay. J Hum Reprod Sci, 2019
• Paediatric reference intervals for plasma anti-Müllerian hormone: comparison of data from the Roche Elecsys assay and the Beckman Coulter Access assay using the same cohort of samples. Ann Clin Biochem, 2020
• Evaluation of meibomian gland morphology and anterior segment parameters by Sirius topography systems in polycystic ovary syndrome. Indian J Ophthalmol, 2022
• Adjusting antimüllerian hormone levels for age and body mass index improves detection of polycystic ovary syndrome. Fertil Steril, 2020
• Body Composition Changes Over the Menopausal Transition in Women With and Without Human Immunodeficiency Virus. Clin Infect Dis, 2023
• Diagnostic Utility of Various Hormones across Different Polycystic Ovary Syndrome Phenotypes: A Cross-sectional Study. J Hum Reprod Sci, 2025
• Serum Anti-Müllerian Hormone in the Diagnosis of Polycystic Ovary Syndrome in Association with Clinical Symptoms. Diagnostics (Basel), 2019
• Markers of ovarian reserve as predictors of future fertility. Fertil Steril, 2023
• Use of AMH in the Differential Diagnosis of Anovulatory Disorders Including PCOS. Front Endocrinol (Lausanne), 2021
• Variation in the Measurement of Anti-Müllerian Hormone - What Are the Laboratory Issues? Front Endocrinol (Lausanne), 2022
• Switch to Integrase Strand Transfer Inhibitors During the Menopausal Transition Is Associated With Accelerated Body Composition Change in Women With HIV. Clin Infect Dis, 2025
• Controversies in the diagnosis of polycystic ovary syndrome. Ther Adv Reprod Health, 2020
• Non-equivalence of anti-Müllerian hormone automated assays-clinical implications for use as a companion diagnostic for individualised gonadotrophin dosing. Hum Reprod, 2018
• Threshold value of anti-Mullerian hormone for the diagnosis of polycystic ovary syndrome in Chinese women. PLoS One, 2019
• Serum anti-Müllerian hormone: A potential biomarker for polycystic ovary syndrome. Indian J Med Res, 2023
• Polycystic ovary syndrome phenotype does not have impact on oocyte morphology. Reprod Biol Endocrinol, 2022